Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101

Ken B Waites; D M Crabb; Lynn B Duffy

doi:10.1128/AAC.00090-09

Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101

Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.

Authors

Ken B Waites¹, D M Crabb, Lynn B Duffy

Affiliation

¹ Department of Pathology, 619 19th Street South, WP 230, University of Alabama at Birmingham, Birmingham, AL 35249, USA. waiteskb@uab.edu

Abstract

MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Drug Resistance, Bacterial
Humans
Ketolides / pharmacology*
Microbial Sensitivity Tests
Mycoplasma / classification
Mycoplasma / drug effects*
Mycoplasma / isolation & purification
Mycoplasma Infections / microbiology
Mycoplasma fermentans / drug effects
Mycoplasma fermentans / isolation & purification
Mycoplasma genitalium / drug effects
Mycoplasma genitalium / isolation & purification
Mycoplasma pneumoniae / drug effects
Ureaplasma / classification
Ureaplasma / drug effects*
Ureaplasma / isolation & purification
Ureaplasma Infections / microbiology

Substances

Anti-Bacterial Agents
Ketolides